Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Retained Earnings (2020 - 2026)

Rani Therapeutics Holdings' Retained Earnings history spans 7 years, with the latest figure at -$139.6 million for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 26.72% to -$139.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$139.6 million, a 26.72% decrease, with the full-year FY2025 number at -$132.6 million, down 2651700.0% from a year prior.
  • Retained Earnings came in at -$139.6 million for Q1 2026, down from -$132.6 million in the prior quarter.
  • The five-year high for Retained Earnings was $5000.0 in Q4 2024, with the low at -$139.6 million in Q1 2026.
  • Historically, Retained Earnings has averaged -$55.7 million across 5 years, with a median of -$47.3 million in 2023.
  • Biggest five-year swings in Retained Earnings: skyrocketed 100.01% in 2024 and later tumbled 2651700.0% in 2025.
  • Year by year, Retained Earnings stood at -$38.9 million in 2022, then crashed by 87.28% to -$72.9 million in 2023, then soared by 100.01% to $5000.0 in 2024, then plummeted by 2651700.0% to -$132.6 million in 2025, then fell by 5.3% to -$139.6 million in 2026.
  • Business Quant data shows Retained Earnings for RANI at -$139.6 million in Q1 2026, -$132.6 million in Q4 2025, and -$122.3 million in Q3 2025.